Jack Bendheim Sells 7,040 Shares of Phibro Animal Health (NASDAQ:PAHC) Stock

Phibro Animal Health Corporation (NASDAQ:PAHC) CEO Jack Bendheim sold 7,040 shares of the stock in a transaction on Friday, February 20th. The stock was sold at an average price of $51.42, for a total transaction of $361,996.80. Following the completion of the transaction, the chief executive officer directly owned 22,600 shares in the company, valued at $1,162,092. The trade was a 23.75% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Jack Bendheim also recently made the following trade(s):

• On Wednesday, February 18th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.40, for a total transaction of $361,856.00.
• On Friday, February 13th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.96, for a total transaction of $365,798.40.
• On Wednesday, February 11th, Jack Bendheim sold 14,184 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.62, for a total value of $732,178.08.
• On Tuesday, February 10th, Jack Bendheim sold 58,014 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.81, for a total value of $3,005,705.34.
• On Thursday, February 5th, Jack Bendheim sold 110,842 shares of Phibro Animal Health stock. The stock was sold at an average price of $48.38, for a total value of $5,362,535.96.
• On Wednesday, February 4th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The stock was sold at an average price of $41.15, for a total value of $144,848.00.
• On Tuesday, February 3rd, Jack Bendheim sold 9,660 shares of Phibro Animal Health stock. The shares were sold at an average price of $41.47, for a total value of $400,600.20.
• On Friday, January 30th, Jack Bendheim sold 6,693 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.09, for a total value of $268,322.37.
• On Thursday, January 29th, Jack Bendheim sold 6,772 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.12, for a total value of $271,692.64.
• On Friday, January 23rd, Jack Bendheim sold 1,235 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.55, for a total value of $50,079.25.

Phibro Animal Health Stock Down 0.1%

Shares of NASDAQ PAHC opened at $51.46 on Wednesday. The stock has a market capitalization of $2.09 billion, a P/E ratio of 22.87, a PEG ratio of 0.79 and a beta of 0.80. Phibro Animal Health Corporation has a one year low of $16.16 and a one year high of $56.30. The firm’s 50 day simple moving average is $42.88 and its two-hundred day simple moving average is $40.48. The company has a debt-to-equity ratio of 2.14, a current ratio of 3.05 and a quick ratio of 1.22.

Phibro Animal Health (NASDAQ:PAHC) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $0.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.69 by $0.18. Phibro Animal Health had a net margin of 6.29% and a return on equity of 38.28%. The company had revenue of $373.91 million during the quarter, compared to analysts’ expectations of $355.64 million. Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. As a group, analysts expect that Phibro Animal Health Corporation will post 1.95 EPS for the current fiscal year.

Phibro Animal Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 25th. Stockholders of record on Wednesday, March 4th will be issued a $0.12 dividend. The ex-dividend date is Wednesday, March 4th. This represents a $0.48 annualized dividend and a dividend yield of 0.9%. Phibro Animal Health’s payout ratio is currently 21.33%.

Hedge Funds Weigh In On Phibro Animal Health

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Caitlin John LLC purchased a new stake in Phibro Animal Health in the fourth quarter worth $266,000. Mackenzie Financial Corp raised its holdings in Phibro Animal Health by 7.1% in the 4th quarter. Mackenzie Financial Corp now owns 50,619 shares of the company’s stock worth $1,895,000 after purchasing an additional 3,355 shares in the last quarter. XTX Topco Ltd lifted its position in shares of Phibro Animal Health by 125.4% in the 4th quarter. XTX Topco Ltd now owns 16,233 shares of the company’s stock worth $606,000 after purchasing an additional 9,032 shares during the period. Zacks Investment Management boosted its stake in shares of Phibro Animal Health by 13.2% during the 4th quarter. Zacks Investment Management now owns 91,391 shares of the company’s stock valued at $3,414,000 after purchasing an additional 10,642 shares in the last quarter. Finally, VARCOV Co. purchased a new position in shares of Phibro Animal Health during the fourth quarter valued at about $672,000. Institutional investors own 99.34% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Weiss Ratings restated a “buy (b-)” rating on shares of Phibro Animal Health in a research report on Monday, December 29th. Morgan Stanley set a $49.00 target price on shares of Phibro Animal Health in a report on Friday, February 6th. JPMorgan Chase & Co. lifted their target price on shares of Phibro Animal Health from $45.00 to $50.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th. Finally, Zacks Research lowered shares of Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a report on Monday, February 9th. Two equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Phibro Animal Health currently has an average rating of “Hold” and an average price target of $37.50.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.